pteridines has been researched along with Myelodysplastic Syndromes in 3 studies
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dill, V | 1 |
| Kauschinger, J | 1 |
| Hauch, RT | 1 |
| Buschhorn, L | 1 |
| Odinius, TO | 1 |
| Müller-Thomas, C | 1 |
| Mishra, R | 1 |
| Kyncl, MC | 1 |
| Schmidt, B | 1 |
| Prodinger, PM | 1 |
| Hempel, D | 1 |
| Bellos, F | 1 |
| Höllein, A | 1 |
| Kern, W | 1 |
| Haferlach, T | 1 |
| Slotta-Huspenina, J | 1 |
| Bassermann, F | 1 |
| Peschel, C | 1 |
| Götze, KS | 1 |
| Waizenegger, IC | 1 |
| Höckendorf, U | 1 |
| Jost, PJ | 1 |
| Jilg, S | 1 |
| Geyh, S | 1 |
| Rodríguez-Paredes, M | 1 |
| Jäger, P | 1 |
| Koch, A | 1 |
| Bormann, F | 1 |
| Gutekunst, J | 1 |
| Zilkens, C | 1 |
| Germing, U | 1 |
| Kobbe, G | 1 |
| Lyko, F | 1 |
| Haas, R | 1 |
| Schroeder, T | 1 |
| Zhou, L | 1 |
| Nguyen, AN | 1 |
| Sohal, D | 1 |
| Ying Ma, J | 1 |
| Pahanish, P | 1 |
| Gundabolu, K | 1 |
| Hayman, J | 1 |
| Chubak, A | 1 |
| Mo, Y | 1 |
| Bhagat, TD | 1 |
| Das, B | 1 |
| Kapoun, AM | 1 |
| Navas, TA | 1 |
| Parmar, S | 1 |
| Kambhampati, S | 1 |
| Pellagatti, A | 1 |
| Braunchweig, I | 1 |
| Zhang, Y | 1 |
| Wickrema, A | 1 |
| Medicherla, S | 1 |
| Boultwood, J | 1 |
| Platanias, LC | 1 |
| Higgins, LS | 1 |
| List, AF | 1 |
| Bitzer, M | 1 |
| Verma, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs)[NCT04103645] | Phase 2 | 37 participants (Anticipated) | Interventional | 2019-11-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pteridines and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Cell Cycle Proteins; Female; Gene Expression Regu | 2020 |
2 other studies available for pteridines and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Fe | 2018 |
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.
Topics: Aged; Aged, 80 and over; Animals; Antigens, CD34; Bone Marrow; Female; Hematopoiesis; Humans; Lentiv | 2008 |